Biohaven (BHVN) Non-Current Debt (2025 - 2026)

Biohaven's (BHVN) quarterly Non-Current Debt came in at $241.9 million in Q1 2026, up 1.26% quarter-over-quarter from $238.9 million in Q4 2025.

Biohaven (BHVN) Non-Current Debt (2025 - 2026) Analysis & Trends

Biohaven has disclosed Non-Current Debt across 2 years of filings, most recently posting $241.9 million for Q1 2026.

Non-Current Debt for Q1 2026 came in at $241.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $241.9 million (changed N/A YoY), and the FY2025 annual result was $238.9 million, changed N/A from the prior year.
Non-Current Debt came in at $241.9 million for Q1 2026 at Biohaven, up from $238.9 million in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $268.3 million in Q3 2025 to a low of $238.9 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	319.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Biohaven	1.62 Bn	1.27 Bn	-	241.91 Mn

Download Data